Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter 2011 and Full Year 2011 Results
Date:2/14/2012

,515)-211%Tax provision (benefit)

(444)2,077(2,521)-121%Net income (loss)

(9,802)7,192(16,994)-236%Diluted net income (loss) per share

$
(0.35)$
.25$
(0.60)-240%Fourth Quarter 2011 Key Financial Figures(1)Three Months EndedDecember 31September 30(in thousands, except per share amounts)

20112011Change ($)Change (%)Total revenues

$
8,370$
7,969$
4015%Research & development  expenses

10,5568,1742,38229%General & administrative expenses

3,3452,71163423%Non-cash stock-based compensation(2)

1,3181,254645%Loss before tax provision

(5,809)(3,187)(2,622)-82%Tax benefit

(286)(113)(173)-153%Net loss

(5,523)(3,074)(2,449)-80%Diluted net loss per share

$
(0.20)$
(0.11)$
(0.09)-82%Select Cash Flow Data(1) Twelve Months EndedDecember 31December 31(in thousands)

20112010Net cash provided by (used in)Operating activities

(28,410)(10,898)Investing activities

73,749(155,622)Financing activities

253,784Net change in cash and cash equivalents

$
45,364$
(162,736)Select Balance Sheet Data(1) December 31September 30December 31(in thousands)

201120112010Total cash and marketable securities

$
7,896$
80,459$
98,037(1) Unaudited(2) Non-cash stock-based compensation is allocated to both Research & development and General & administrative expenses OPERATIONAL HIGHLIGHTS   On January 26, 2012, Vanda announced that initial clinical data in the RESET study revealed the potential of tasimelteon to reset the body clock in Non-24-Hour Disorder.  The tasimelteon Non-24-Hour Disorder program continues to advance towards a projected mid-2013 NDA filing with the FDA.   Vanda is in continuing discussions with the FDA to confirm the path and requirements for this regulatory submission.  Vanda expects to complete the two Phase III efficacy studies, SET and RESET, b
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Presents Phase III Iloperidone Efficacy Data
5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Research and Markets ... Cancer Therapeutics Market & Pipeline Insight 2014" report ... developed to prevent and eradicate the prevalence of cancer ... are confined to low specificity, safety and large number ... for a better solution. It has been discovered that ...
(Date:8/29/2014)... Aug. 29, 2014  United Therapeutics Corporation (NASDAQ: ... Court for the District of New Jersey ... company,s case against Sandoz, Inc. regarding United Therapeutics, Remodulin ... ruled that U.S. Patent No. 6,765,117 is both ... from marketing its generic product until the expiration of ...
(Date:8/29/2014)... -- ChemImage will present a workshop focused on hyperspectral ... Science Society,s 22 nd International Symposium on ... .  Forensic Scientists will be in attendance ... can bring to examination procedures. ... Development at ChemImage, will host a workshop during ...
Breaking Medicine Technology:Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... , LARGO, Fla., Dec. 22 Unilens Vision Inc. ... that the shareholders of Unilens Vision Inc. voted overwhelmingly in ... at the extraordinary general meeting of its shareholders held yesterday. ... common shares (or 48.9%) were voted at the meeting with ...
... , HONG KONG, Dec. 22 /PRNewswire-Asia/ ... human health in a pioneering medical,field. On Dec. 20, 2009, ... Conference of Endoscopic Physicians. It,s been an honor,to have him ... benefiting human health. , "Endoscopic medicine ...
Cached Medicine Technology:Unilens Announces Extraordinary Meeting Results 2Olympic Winner Xiong Ni, Spokesperson for Endoscopic Medicine -- Chinese Minimally Invasive Advanced Technology Top in the World 2Olympic Winner Xiong Ni, Spokesperson for Endoscopic Medicine -- Chinese Minimally Invasive Advanced Technology Top in the World 3
(Date:8/30/2014)... (PRWEB) August 30, 2014 Ticket ... U.S. Open Tennis Championship tickets in NYC. ... promo/coupon code US-OPEN-2014 for all day session, evening session, ... group sales for this prestigious Grand Slam Tournament. , ... , 8/30/14 , US Open Tennis Championship: Men's/Women's 3rd ...
(Date:8/30/2014)... August 30, 2014 After offering ... country for the past several years, Dr. Roy ... Center have announced a scholarship program for veterans ... follows a meeting held this summer to discuss ... years, reporters have shed light on the large ...
(Date:8/30/2014)... TX (PRWEB) August 30, 2014 ... Disruptor Industry, 2009-2019 is a professional and in-depth ... industry. The report firstly reviews the basic information ... manufacturing technology. The report then explores global and ... product specification, capacity, Production value, and market share ...
(Date:8/30/2014)... 2014 Hundreds of Byetta lawsuits ( ... move forward in U.S. courts, Bernstein Liebhard LLP reports. ... July 31, 2014, Byetta and Bydureon (an extended-release version ... claims that allege the drugs caused pancreatitis, pancreatic cancer ... these claims are pending in a multidistrict litigation underway ...
(Date:8/30/2014)... Rapids, MI (PRWEB) August 30, 2014 ... residents, Forefront Dermatology is expanding with the addition of ... Dr. David Hammond who has provided leading-edge skin care ... with Forefront Dermatology. , “As a doctor, my ... they deserve. Through partnering with Forefront Dermatology, I’m better ...
Breaking Medicine News(10 mins):Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Expanding Care at the Forefront of Dermatology 2
... choice is influenced by physicians, preferences, research suggests ... kind of treatment received by a prostate cancer patient ... patient,s care, new research shows. , U.S. researchers analyzed ... and older who were diagnosed with prostate cancer between ...
... among normal-weight patients , TUESDAY, March 9 (HealthDay News) ... obese face tougher survival odds following treatment compared with ... finding builds on prior research that established that being ... the first place. , "Previous studies have shown that ...
... The ... health, fertility health, and women,s health. , ... Edmonton, Alberta (PRWEB) March 9, 2010 -- The Pregnancy Health ... gives Canadian women important and potentially life-changing information about pregnancy health, fertility health, and ...
... ... Nine innovative healthcare companies have been named Finalists and ... at the 12th Annual Innovations in HealthcareSM Awards Event, on April ... awards honor companies which have proven ways to lower the cost ...
... ... (APNY), a group of 18 established and highly regarded pediatrics practices in Queens, Nassau and ... of their care to extend to thousands more New York children than in the past. ... (Vocus) March 9, 2010 ...
... ... & Cold and Allergy Conference. It is a nasal-sinus irrigation system with a patented ... risk of sinus re-infection, growing concerns in the medical community. The device is also ... ...
Cached Medicine News:Health News:Doctor's Specialty Often Steers Prostate Cancer Care 2Health News:Obese Colon Cancer Survivors Face Poorer Prognosis 2Health News:Obese Colon Cancer Survivors Face Poorer Prognosis 3Health News:Obese Colon Cancer Survivors Face Poorer Prognosis 4Health News:Pregnancy Health Centre Launches Website to Help Women 2Health News:Nine Healthcare Companies Named Finalists for Innovations in HealthcareSM ABBY Awards, to be Presented April 28th 2Health News:Nine Healthcare Companies Named Finalists for Innovations in HealthcareSM ABBY Awards, to be Presented April 28th 3Health News:Nine Healthcare Companies Named Finalists for Innovations in HealthcareSM ABBY Awards, to be Presented April 28th 4Health News:Nine Healthcare Companies Named Finalists for Innovations in HealthcareSM ABBY Awards, to be Presented April 28th 5Health News:Long Island Pediatric Group Announces Policy Changes That Will Help More New Yorkers 2Health News:Long Island Pediatric Group Announces Policy Changes That Will Help More New Yorkers 3Health News:TechWorld Medicals NasalCare Nasal Cleanse Kit Named “Best New Product” at ECRM Cough & Cold and Allergy Conference 2Health News:TechWorld Medicals NasalCare Nasal Cleanse Kit Named “Best New Product” at ECRM Cough & Cold and Allergy Conference 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: